[ CAS No. 1150271-44-5 ] 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Cat. No.: A181793

2D 3D

Structure of 1150271-44-5 * Storage: Keep in dark place,Inert atmosphere,Room temperature

Purity	Size	Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
95%	100mg	$41.00	Inquiry	Inquiry
95%	250mg	$66.00	Inquiry	Inquiry
95%	1g	$169.00	Inquiry	Inquiry
95%	5g	$607.00	Inquiry	Inquiry

Search after Editing

* Storage: Keep in dark place,Inert atmosphere,Room temperature

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1150271-44-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1150271-44-5 ]

Specification

Alternatived Products of [ 1150271-44-5 ]

Product Details of [ 1150271-44-5 ]

CAS No. :	1150271-44-5	MDL No. :	MFCD11504971
Formula :	C₁₄H₁₈BNO₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	LDDMKYKRLRAKPL-UHFFFAOYSA-N
M.W :	259.11	Pubchem ID :	46739223
Synonyms :

Calculated chemistry of [ 1150271-44-5 ] Expand+

Safety of [ 1150271-44-5 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1150271-44-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 1150271-44-5 ]
Downstream synthetic route of [ 1150271-44-5 ]

[ 1150271-44-5 ] Synthesis Path-Upstream 1~1

1
[ 99365-48-7 ]
[ 73183-34-3 ]
[ 1150271-44-5 ]

Yield	Reaction Conditions	Operation in experiment
74%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂; potassium acetate In 1,4-dioxane at 110℃; for 2 h; Sealed tube; Microwave irradiation	Intermediate 114: 4-(4,4,5,5-Tetramethyl-1 ,2-dioxaborolan-2-yl)indolin-2-one (0793) A mixture of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (1.903 g, 7.49 mmol, commercially available from, for example, Fluorochem), 4-bromoindolin-2-one (1.038 g, 4.90 mmol, commercially available from, for example, Fluorochem), [1,1'- 7 s(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane [Pd(dppf)Cl2.DCM] (0.601 g, 0.73 mmol) and potassium acetate (1.480 g, 15.08 mmol) in 1,4-dioxane (30 mL) was stirred at 110 °C for 2 h. The mixture was allowed to cool to rt before being filtered through a 10 g celite cartridge. The cartridge was washed through with ethyl acetate (3 x 30 mL) and the combined filtrates were evaporated in vacuoto give a brown liquid which was re-dissolved in DCM (ca. 10 mL), loaded onto a 100 g SNAP silica cartridge and purified by Biotage SP4 semi-automated flash column chromatography eluting with a gradient of 20 to 50percent ethyl acetate in cyclohexane. The required fractions were combined and evaporated in vacuo, this was re-dissolved in DCM (ca. 10 mL), transferred to a tarred vial and the solvent evaporated under a stream of nitrogen. The residue was triturated with ether (5 x 5 mL), decanting away the mother liquor each time, and the residue dried under a stream of nitrogen and in vacuo to give the desired product 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)indolin-2-one (941.8 mg, 3.63 mmol, 74 percent yield) as a cream solid. (0794) LCMS (2 min Formic): Rt = 0.93 min, [MH]+ = 260.3.
74.2%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂; potassium acetate In 1,4-dioxane at 110℃; for 2 h;	A mixture of 4,4,4T,4T,5,5,5T,5T-octamethyl-2,2T-bi( 1,3, 2-d ioxaborolane) (1.9025 g, 7.49 mmol), 4-bromoindolin-2-one (1.0383 g, 4.90 mmol), [1,1’-Bis(d iphenylphosphino)ferrocene]dichloropallad ium(II), complex with dichloromethane (0.6005 g,0.734 mmol) and potassium acetate (1.4802 g, 15.08 mmol) in 1,4-Dioxane (30 mL) was stirred at110 °C for 2 hr. The mixture was allowed to cool to room temperature before being filtered througha lOg celite cartridge. The cartridge was washed through with ethyl acetate (3 x 30 mL) and thecombined filtrates were evaporated in vacuo to give to give a brown liquid, which was redissolved indichloromethane (ca. 10 mL), loaded onto a bOg SNAP silica cartridge and purified by Biotage 5P4semi-automated flash column chromatography eluting with a gradient of 20 to 50percent ethyl acetate incyclohexane. The required fractions were combined and evaporated in vacuo, the residue (which was on the verge of crystallisation) was re-dissolved in dichloromethane (ca. 10 mL), transferred to a tared vial, the solvent evaporated under a stream of nitrogen. The residue was triturated with ether (5 x 5 mL), decanting away the mother liquor each time, and the residue dried under a stream of nitrogen and in vacuoto give the desired product as a cream solid (941.8 mg, 3.63 mmol, 74.2 percent yield)LCMS (2 mm Formic): Rt = 0.93 mi [MH]+ = 260

Reference： [1] Patent: WO2017/174621, 2017, A1, . Location in patent: Page/Page column 88
[2] Patent: WO2017/202742, 2017, A1, . Location in patent: Page/Page column 42; 43; 97; 98

[ 1150271-44-5 ] Synthesis Path-Downstream 1~16

2
[ 1150271-44-5 ]
[ 1000342-95-9 ]
[ 76-05-1 ]
4-(6-(trifluoromethyl)-1H-indazol-4-yl)indolin-2-one trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
46%		EXAMPLE 129: 4-(6-(trifluoromethyl)-lH-indazol-4-yl)indolin-2-one [0548] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.026 g, 0.096 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indolin-2-one (0.025 g, 0.096 mmol) and PdCl2(dppf) (3.53 mg, 4.82 muiotaetaomicron) in dioxane (4 mL) and aqueous saturated NaHC03 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with 30percent ACN (containing 0.035percent) TFA) in H20 (containing 0.05percent TFA) over a period of 10 minutes. The product-containing fractions were combined and volatiles evaporated in vacuo to give a TFA salt of the title compound as a light brown solid (0.014 g, 0.044 mmol, 46percent). 1H NMR (400 MHz, DMSO- d6) delta ppm 3.50 (s, 2 H), 6.94 (d, J=7.58 Hz, 1 H), 7.17 (dd, J=7.96, 0.88 Hz, 1 H), 7.29-7.44 (m, 1 H), 7.46-7.53 (m, 1 H), 7.94 (s, 1 H), 8.15 (s, 1 H), 10.55 (s, 1 H), 13.70 (s, 1 H); ESI- MS m/z [M+H]+ calc'd for C16H10F3N3O, 318.1; found 318.15.

Reference： [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0547; 0548

3
[ 1150271-44-5 ]
4-[4-chloro-6-(morpholin-4-yl)-8-oxa-3,5,1 0triazatricyclo[7.4.0.02,7]trideca1(13),2(7),3,5,9,11-hexaen-12-yl]methyl}-1λ4-thiomorpholin-1-one [ No CAS ]
4-[6-(morpholin-4-yI)-12-[(1-oxo-1λ4-thiomorpholin-4-yI)methyl]-8-oxa-3,5,10-triazatricycIo[7.4.0.02,7]trideca-1(13),2(7),3,5,9,11-hexaen-4-yI]-2,3-dihydro-1H-indol-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%	With bis-triphenylphosphine-palladium(II) chloride; sodium carbonate; In 1,4-dioxane; water; at 90℃; for 2h;Inert atmosphere; Microwave irradiation;	To a microwave vial containing Intermediate 8 (117 mg, 0.278 mmol, 1.0 eq), <strong>[1150271-44-5](2-oxoindolin-4-yl)boronic acid pinacol ester</strong> (152 mg, 0.556 mmol, 2.0 eq), sodium carbonate (58.9 mg, 0.556 mmol, 2.0 eq) and PdCl2(PPh3)2 (39.0 mg, 0.0556 mmol, 20 mol%) was added 1,4-dioxane (1.1 mL) and H20 (0.3 mL). Thesuspension was stirred at 90C for 1 h in a microwave reactor then cooled to rt. An additional portion of PdCI2(PPh3)2 (19.5 mg, 0.0278 mmol, 10 mol%) was added and the reaction mixture was heated at 90C for a further 1 h in the microwave. Upon cooling, the mixture was diluted with CH2CI2 (20 mL) and washed with H20 (20 mL). The aqueous layer was concentrated in vacuo andpurified by silica gel column chromatography with CH2CI2/MeOH (1:0-9:1). The product was re-dissolved in CH2CI2/MeOH (4:1, 15 mL) and swirled with prewashed MP-TMT resin (200 mg, 0.220 mmol, 3 eq wrt Pd) at rtfor 17 h. The solution was filtered and the resin washed with CH2CI2/MeOH (4:1, 100 mL) to yield Example N as an off-white solid (79.7 mg, 55%).1H NMR (300MHz, DMSO-d5) oH. 10.49 (5, 1H), 8.62 (br 5, 2H), 8.02 (d, J=8.1Hz, 1H), 7.34 (t, J=7.8 Hz, 1H), 6.95 (d, J=7.5 Hz, 1H), 4.04-4.18 (m, 4H), 3.99(5, 2H), 3.73-3.93 (m, 6H), 2.85-3.06 (m, 4H), 2.66-2.84 (m, 4H).MS (ESj 519.2 (100%, [M+H]j, 541.2 (12%, [M+Na]j.

Reference： [1]Patent: WO2017/29521,2017,A1 .Location in patent: Page/Page column 80

4
[ 1150271-44-5 ]
cis-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one [ No CAS ]
cis-8-dimethylamino-3-[2-(2-oxo-1,3-dihydroindol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
76%	With bis(tri-t-butylphosphine)palladium(0); sodium carbonate; In tetrahydrofuran; water; at 23 - 60℃;	CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-l,3-diazaspiro[4.5]decan-2-one (INT- 989) (150 mg, 0.38 mmol), Pd(t-Bu3P)2 (0.1 equiv., 0.02 mmol, 10 mg) and 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)indolin-2-one (2 equiv., 0.78 mmol, 201 mg) were dissolved in degassed anhydrous THF (80 equiv., 31 mmol, 2.5 mL) and 1M aq. Na2CO3 (5.5 equiv., 2.14 mmol, 2.14 mL) was added. The resulting mixture was stirred at 60C for 8 h and then at RT overnight. The reaction mixture was diluted with water until precipitation occurred. The precipitate was filtered off, suspended in 30 mL DCM, filtered off again, washed with pentane (5 mL) and dried under reduced pressure to give 143 mg (76%) of CIS-4-(5-(8-(dimethylamino)-2- oxo-8-phenyl-l ,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)indolin-2-one (SC_3208). :H NMR (600 MHz, DMSO) delta 10.45 (s, IH), 9.10 (s, 2H), 7.87 (d, IH), 7.84 - 7.80 (m, IH), 7.39 (d, 5H), 7.29 (dt, 2H), 6.91 (d, IH), 3.82 (s, 2H), 3.72 (s, 2H), 2.41 (d, 2H), 2.03 - 1.74 (m, 9H), 1.60 - 1.44 (m, 3H). Mass: m/z 484.26 (M+H)+.

Reference： [1]Patent: WO2017/121647,2017,A1 .Location in patent: Paragraph 0390; 0391

5
[ 99365-48-7 ]
[ 73183-34-3 ]
[ 1150271-44-5 ]

Yield	Reaction Conditions	Operation in experiment
74%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In 1,4-dioxane; at 110℃; for 2h;Sealed tube; Microwave irradiation;	Intermediate 114: 4-(4,4,5,5-Tetramethyl-1 ,2-dioxaborolan-2-yl)indolin-2-one (0793) A mixture of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (1.903 g, 7.49 mmol, commercially available from, for example, Fluorochem), <strong>[99365-48-7]4-bromoindolin-2-one</strong> (1.038 g, 4.90 mmol, commercially available from, for example, Fluorochem), [1,1'- 7 s(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane [Pd(dppf)Cl2.DCM] (0.601 g, 0.73 mmol) and potassium acetate (1.480 g, 15.08 mmol) in 1,4-dioxane (30 mL) was stirred at 110 C for 2 h. The mixture was allowed to cool to rt before being filtered through a 10 g celite cartridge. The cartridge was washed through with ethyl acetate (3 x 30 mL) and the combined filtrates were evaporated in vacuoto give a brown liquid which was re-dissolved in DCM (ca. 10 mL), loaded onto a 100 g SNAP silica cartridge and purified by Biotage SP4 semi-automated flash column chromatography eluting with a gradient of 20 to 50% ethyl acetate in cyclohexane. The required fractions were combined and evaporated in vacuo, this was re-dissolved in DCM (ca. 10 mL), transferred to a tarred vial and the solvent evaporated under a stream of nitrogen. The residue was triturated with ether (5 x 5 mL), decanting away the mother liquor each time, and the residue dried under a stream of nitrogen and in vacuo to give the desired product 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)indolin-2-one (941.8 mg, 3.63 mmol, 74 % yield) as a cream solid. (0794) LCMS (2 min Formic): Rt = 0.93 min, [MH]+ = 260.3.
74.2%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In 1,4-dioxane; at 110℃; for 2h;	A mixture of 4,4,4T,4T,5,5,5T,5T-octamethyl-2,2T-bi( 1,3, 2-d ioxaborolane) (1.9025 g, 7.49 mmol), <strong>[99365-48-7]4-bromoindolin-2-one</strong> (1.0383 g, 4.90 mmol), [1,1?-Bis(d iphenylphosphino)ferrocene]dichloropallad ium(II), complex with dichloromethane (0.6005 g,0.734 mmol) and potassium acetate (1.4802 g, 15.08 mmol) in 1,4-Dioxane (30 mL) was stirred at110 C for 2 hr. The mixture was allowed to cool to room temperature before being filtered througha lOg celite cartridge. The cartridge was washed through with ethyl acetate (3 x 30 mL) and thecombined filtrates were evaporated in vacuo to give to give a brown liquid, which was redissolved indichloromethane (ca. 10 mL), loaded onto a bOg SNAP silica cartridge and purified by Biotage 5P4semi-automated flash column chromatography eluting with a gradient of 20 to 50% ethyl acetate incyclohexane. The required fractions were combined and evaporated in vacuo, the residue (which was on the verge of crystallisation) was re-dissolved in dichloromethane (ca. 10 mL), transferred to a tared vial, the solvent evaporated under a stream of nitrogen. The residue was triturated with ether (5 x 5 mL), decanting away the mother liquor each time, and the residue dried under a stream of nitrogen and in vacuoto give the desired product as a cream solid (941.8 mg, 3.63 mmol, 74.2 % yield)LCMS (2 mm Formic): Rt = 0.93 mi [MH]+ = 260
	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate; In 1,4-dioxane; at 80℃; for 12h;Inert atmosphere;	A mixture of <strong>[99365-48-7]4-bromoindolin-2-one</strong> (500.0 mg, 2.36 mmol), B2pin2 (898.2mg, 3.54 mmol), KOAc (462.8 mg, 4.72 mmol), Pd(dppt)Ch (172.5 mg, 235.80 umol) indioxane (20 mL) was degassed and purged with N2 for 3 times, and then the mixture wasstirred at 80 oc for 12h under N2 atmosphere. The mixture was concentrated and theresulting residue was purit1ed by column chromatography (Si02, Petroleum ether/Ethylacetate= 10/1 to 0:1). Compound 115A (600.0 mg, crude) was obtained as a yellow solid.Tiw crude product was used in next step directly.

Reference： [1]Patent: WO2017/174621,2017,A1 .Location in patent: Page/Page column 88
[2]Patent: WO2017/202742,2017,A1 .Location in patent: Page/Page column 42; 43; 97; 98
[3]Patent: WO2019/190885,2019,A1 .Location in patent: Paragraph 0469

6
[ 1150271-44-5 ]
(±)-tert-butyl 2-(methylcarbamoyl)-6-(1-(2-oxoindolin-4-yl)ethyl)isonicotinate [ No CAS ]

Reference： [1]Patent: WO2017/174621,2017,A1
[2]Patent: WO2017/202742,2017,A1

7
[ 1150271-44-5 ]
(±)-2-(methylcarbamoyl)-6-(1-(2-oxoindolin-4-yl)ethyl)isonicotinic acid [ No CAS ]

Reference： [1]Patent: WO2017/174621,2017,A1
[2]Patent: WO2017/202742,2017,A1

8
[ 1150271-44-5 ]
(±)-N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N2-methyl-6-(1-(2-oxoindolin-4-yl)ethyl)pyridine-2,4-dicarboxamide [ No CAS ]

Reference： [1]Patent: WO2017/174621,2017,A1

9
[ 1150271-44-5 ]
(±)-N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N2-methyl-6-((R)-1-(2-oxoindolin-4-yl)ethyl)pyridine-2,4-dicarboxamide [ No CAS ]
(±)-N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N2-methyl-6-((S)-1-(2-oxoindolin-4-yl)ethyl)pyridine-2,4-dicarboxamide [ No CAS ]

Reference： [1]Patent: WO2017/174621,2017,A1

10
[ 1150271-44-5 ]
tert-butyl 2-(1-bromovinyl)-6-(methylcarbamoyl)isonicotinate [ No CAS ]
tert-butyl 2-(methylcarbamoyl)-6-(1-(2-oxoindolin-4-yl)vinyl)isonicotinate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
56%	With potassium phosphate; [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride; In 1,4-dioxane; water; at 20℃; for 19h;Inert atmosphere; Darkness;	Intermediate 176: te -Butyl 2-(methylcarbamov0-6-(l-(2-oxoindolin-4- vOvinvOisonicotinate (1022) (1023) A solution of fe/f-butyl 2-(l-bromovinyl)-6-(methylcarbamoyl)isonicotinate (350 mg, 0.72 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indolin-2-one (276.9 mg, 1.07 mmol), [1,3- 7/5(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride (PEPPSI-iPr) (71.0 mg, 0.10 mmol) and tripotassium phosphate (566.8 mg, 2.67 mmol) in 1,4-dioxane (6 mL) and water (3 mL) was stirred under nitrogen at rt in the dark for 19 h. The reaction mixture was filtered through a 2.5 g celite cartridge and the cartridge washed with ethyl acetate (approx. 10 mL). To the filtrate was added water (5 mL) and brine (5 mL) and the layers separated. The aqueous layer was extracted with further ethyl acetate (2 x 10 mL) and the organic phases were combined and filtered through a cartridge fitted with a hydrophobic frit. The filtrate was evaporated in vacuoto give a sticky brown solid (556.7 mg). This was redissolved in DMSO (6 mL) and directly purified by MDAP (high pH). The required fractions were combined and evaporated in vacuo to give fe/f-butyl 2- (methylcarbamoyl)-6-(l-(2-oxoindolin-4-yl)vinyl)isonicotinate (157.7 mg, 0.40 mmol, 56 % yield) as a light yellow solid. (1024) LCMS (2 min High pH): Rt = 1.05 min, [MH]+ = 394.4
36.2%	With potassium phosphate; [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride; In 1,4-dioxane; water; at 20℃; for 22.5h;Inert atmosphere; Darkness;	A solution of tert-butyl 2-(1-bromovinyl)-6-(methylcarbamoyl)isonicotinate (380 mg, 0.724 mmol), <strong>[1150271-44-5]4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one</strong> (250.3 mg, 0.966 mmol), [1,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)pallad ium(II) d ichloride (51.9 mg, 0.076 mmol) and tripotassium phosphate (492.6 mg, 2.321 mmol) in 1,4-Dioxane (4.0 mL) and Water (2.0 mL) was stirred at room temperature under nitrogen in the dark for 22.5 hours. To the reaction mixture was added ethyl acetate (15 mL), water (10 mL) and brine (5 mL) and the layers separated. Theaqueous layer was extracted with further ethyl acetate (2 x 15 mL) and the organic phases were combined and filtered through a cartridge fitted with a hydrophobic frit. The filtrate was evaporated in vacuo to give a sticky light brown solid (415.0 mg). This was redissolved in DMSO (4 mL) and methanol (2 mL) and directly purified by (MDAP) (2 x 3 mL injection, high pH). The required fractions were combined and evaporated in vacuo to give the desired product as a yellow solid (103.2 mg,0.262 mmol, 36.2 % yield).LCMS (2 mm High pH): Rt = 1.05 mi [MH]+ = 394

Reference： [1]Patent: WO2017/174621,2017,A1 .Location in patent: Page/Page column 120
[2]Patent: WO2017/202742,2017,A1 .Location in patent: Page/Page column 98

11
[ 1150271-44-5 ]
2-(methylcarbamoyl)-6-((2-oxoindolin-4-yl)methyl)isonicotinic acid [ No CAS ]

Reference： [1]Patent: WO2017/202742,2017,A1

12
[ 1150271-44-5 ]
N₂-methyl-N₄-((1S,2S)-2-methylcyclopropyl)-6-(1-(2-oxoindolin-4-yl)ethyl)pyridine-2,4-dicarboxamide [ No CAS ]

Reference： [1]Patent: WO2017/202742,2017,A1

13
[ 1150271-44-5 ]
N₂-methyl-N₄-((1S,2S)-2-methylcyclopropyl)-6-((2-oxoindolin-4-yl)methyl)pyridine-2,4-dicarboxamide [ No CAS ]

Reference： [1]Patent: WO2017/202742,2017,A1

14
[ 1150271-44-5 ]
tert-butyl 2-(chloromethyl)-6-(methylcarbamoyl)isonicotinate [ No CAS ]
tert-butyl 2-(methylcarbamoyl)-6-((2-oxoindolin-4-yl)methyl)isonicotinate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
33.3%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate; In 1,4-dioxane; water; at 120℃; for 0.666667h;	tert-Butyl 2-(chloromethyl)-6-(methylcarbamoyl)isonicotinate (80 mg, 0.281 mmol) was combined with 4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)indolin-2-one (479 mg, 0.425 mmol, 23% wt.),potassium carbonate (129.9 mg, 0.940 mmol) and PdCI2(dppf) (41.1 mg, 0.056 mmol) in 1,4-dioxane (1 mL) and water (0.5 mL) in a 2 mL microwave vial. This was heated at 120 C for 40 mm. The solution was filtered through Celite (eluent EtOAc) then concentrated to give 198 mg of a black solid. This was purified by chromatography on Si02 (Biotage SNAP 10 g, eluting with lO-S0% ethyl acetate/cyclohexane). The desired fractions were concentrated to give tert-butyl 2-(methylcarbamoyl)-6-((2-oxoindolin-4-yl)methyl)isonicotinate (39.7 mg, 0.094 mmol, 33.3 % yield) as a colourless oil.LCMS (2 mm Formic): Rt = 1.00 mi [MH]+ 382.3.

Reference： [1]Patent: WO2017/202742,2017,A1 .Location in patent: Page/Page column 55; 56

15
[ 1048982-04-2 ]
[ 1150271-44-5 ]
C₁₃H₁₁N₃O₃S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With bis(tri-t-butylphosphine)palladium(0); caesium carbonate; In 1,4-dioxane; water; at 80℃; for 1h;Inert atmosphere;	A mixture of ethyl 4-chloro-1,2,5-thiadiazole-3-carboxylate (446.0 mg,2.32 mmol), compound H5A (600.0 mg, 2.32 mmol), palladium;tritert-butylphosphane(118.3 mg, 231.56 umol), Cs2C03 (2.26 g, 6.95 mmo1) in rhO (5 mL) and dioxane (50 mL)was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 oc for lhr under N2 atmosphere. The mixture was concentrated and the resulting residue waspurified by column chromatography (Si02, Petroleum ether/Ethyl acetate=5/l to 0: l ).Compound 115B (500.0 mg, 50.3% yield, 67.4% purity) was obtained as a yellow solid. MS(ESI) m/z (M+Ht 290.0.

Reference： [1]Patent: WO2019/190885,2019,A1 .Location in patent: Paragraph 0469; 0470

16
[ 1150271-44-5 ]
C₁₁H₇N₃O₃S [ No CAS ]

Reference： [1]Patent: WO2019/190885,2019,A1

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

• Acyl Group Substitution • Baeyer-Villiger Oxidation • Barbier Coupling Reaction • Baylis-Hillman Reaction • Bucherer-Bergs Reaction • Chan-Lam Coupling Reaction • Clemmensen Reduction • Complex Metal Hydride Reductions • Corey-Bakshi-Shibata (CBS) Reduction • Corey-Chaykovsky Reaction • Fischer Indole Synthesis • Grignard Reaction • Henry Nitroaldol Reaction • Horner-Wadsworth-Emmons Reaction • Hydride Reductions • Lawesson's Reagent • Leuckart-Wallach Reaction • McMurry Coupling • Meerwein-Ponndorf-Verley Reduction • Passerini Reaction • Paternò-Büchi Reaction • Petasis Reaction • Peterson Olefination • Pictet-Spengler Tetrahydroisoquinoline Synthesis • Preparation of Aldehydes and Ketones • Preparation of Amines • Prins Reaction • Reactions of Aldehydes and Ketones • Reactions of Amines • Reformatsky Reaction • Robinson Annulation • Schlosser Modification of the Wittig Reaction • Schmidt Reaction • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • Stobbe Condensation • Tebbe Olefination • Ugi Reaction • Wittig Reaction • Wolff-Kishner Reduction

Historical Records

Related Functional Groups of
[ 1150271-44-5 ]

Organoboron

[ 893441-85-5 ]

6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Similarity: 0.94

[ 1220696-38-7 ]

1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Similarity: 0.92

[ 1427587-32-3 ]

1-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one

Similarity: 0.88

[ 935660-75-6 ]

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide

Similarity: 0.85

[ 1062174-44-0 ]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

Similarity: 0.82

Amides

[ 893441-85-5 ]

6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Similarity: 0.94

[ 1220696-38-7 ]

1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Similarity: 0.92

[ 1427587-32-3 ]

1-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one

Similarity: 0.88

[ 935660-75-6 ]

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide

Similarity: 0.85

[ 1235451-62-3 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline-1-carboxylate

Similarity: 0.80

Related Parent Nucleus of
[ 1150271-44-5 ]

Indoles

[ 388116-27-6 ]

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

Similarity: 0.77

[ 1219741-53-3 ]

1-Ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

Similarity: 0.73

[ 642494-36-8 ]

6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

Similarity: 0.72

[ 269410-24-4 ]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

Similarity: 0.72

[ 893441-86-6 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

Similarity: 0.72

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Num. heavy atoms :	19
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.5
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	78.21
TPSA :	47.56 Å²

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	Yes
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.63 cm/s

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	1.76
Log Po/w (WLOGP) :	0.91
Log Po/w (MLOGP) :	1.13
Log Po/w (SILICOS-IT) :	1.74
Consensus Log Po/w :	1.11

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Log S (ESOL) :	-2.72
Solubility :	0.49 mg/ml ; 0.00189 mol/l
Class :	Soluble
Log S (Ali) :	-2.38
Solubility :	1.09 mg/ml ; 0.0042 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.49
Solubility :	0.00837 mg/ml ; 0.0000323 mol/l
Class :	Moderately soluble

[ CAS No. 1150271-44-5 ] 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Quality Control of [ 1150271-44-5 ]

Related Doc. of [ 1150271-44-5 ]

Product Details of [ 1150271-44-5 ]

Calculated chemistry of [ 1150271-44-5 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1150271-44-5 ]

Application In Synthesis of [ 1150271-44-5 ]

[ 1150271-44-5 ] Synthesis Path-Upstream 1~1

[ 1150271-44-5 ] Synthesis Path-Downstream 1~16

Technical Information